Top 20 Pharma and BioPharma Companies

Top 20 Pharma Report

Top 20 Pharma Report

Patent expirations and currency swings were the big stories for Top Pharma revenues in 2012. Cumulatively, our Top 20 companies saw revenues fall 3% to $448 billion last year, although their net income for that span was virtually flat, at $93 billion. Our top six companies all saw revenues fall last year as they reload for the future. The only companies to show double-digit gains relied on generics (Mylan), an acquisition (Teva, getting a full year of Cephalon revenues) or out-and-out sales growth (Gilead). Nonetheless, the ranking remained relatively stable (we included last year’s position in the chart on the right for reference). That likely won’t be the case next year, with shakeups due to further generic erosion and AbbVie’s shift over to the Top Biopharma ranks. In fact, as more Tops Pharmas derive greater shares of revenue from their biologics programs, we may have to rethink the whole Pharma/Biopharma split in a few years. . .

—Gil Y. Roth Editor

Contributors Editor: Gil Y. Roth Associate Editor: Kristin Brooks Contributing Editor: Derek B. Lowe All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com) Pipeline information compiled by Kristin Brooks Revenue information compiled by Gil Roth Photo courtesy of Eli Lilly & Co.

Top 20 Pharma and BioPharma Companies

RANK COMPANY LOCATION SALES
1
Pfizer
66 Hudson Boulevard East, New York, New York, 10001-2192 $51.2 Billion
2
Novartis
Novartis Campus Basel, Baselstadt 4002 CH $46.7 Billion
3
Merck
Rahway, NJ $40.6 Billion
4
Sanofi
46 Avenue de la Grande Armee Paris, 75017 France $38.3 Billion
5
Roche
Grenzacherstrasse Switzerland, 4070 CH $37.6 Billion
6
GlaxoSmithKline
980 Great West Road Brentford, Middlesex TW8 9GS GB $33.8 Billion
7
AstraZeneca
1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge, Cambridgeshire CB2 0AA GB $28 Billion
8
Johnson & Johnson
1 Johnson and Johnson Plaza, New Brunswick, NJ 08903 US $25.4 Billion
9
Lilly
Lilly Corporate Center Indianapolis, Indiana 46285 US $20.6 Billion
10
Teva Pharmaceuticals
124 Dvora HaNevi'a St. Tel Aviv 6944020, Israel $18.5 Billion
11
Bristol Myers Squibb
3401 Princeton Pike Lawrence Township, NJ 08648 US $17.6 Billion
12
Amgen
One Amgen Center Drive Thousand Oaks, CA 91320 US $17.3 Billion
13
Takeda
Japan $17 Billion
14
Boehringer Ingelheim
900 Ridgefield Road, Ridgefield, CT 06877 $14.7 Billion
15
Bayer
Kaiser-Wilhelm-Allee Leverkusen, North Rhine-Westphalia 51373 DE $13.9 Billion
16
Novo Nordisk
Denmark $13.5 Billion
17
Astellas
2375 Waterview Dr Northbrook, Illinois 60062 US $12.2 Billion
18
Daiichi Sankyo
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo Tokyo, 103-8426 JP $11.5 Billion
19
Otsuka
2-16-4 Konan, Minato-ku, Tokyo 108-8241, Japan $10.3 Billion
20
Gilead Sciences
333 Lakeside Drive Foster City, CA 94404 US $9.4 Billion
21
Merck inc.
Frankfurter Strasse 250 64293 Darmstadt Germany $8.2 Billion
22
Mylan
1000 Mylan Boulevard Canonsburg, Pennsylvania 15317 US $6.8 Billion
23
Biogen
225 Binney Street Cambridge, MA 02142 US $5.3 Billion
24
CSL
1020 First Avenue King of Prussia, PA 19406 US $4.6 Billion
25
Allergan
Longphort House, Block J, Leeson Street Lower, Saint Kevin's, Dublin 2, D02 NY60, Ireland $1.8 Billion